(Q37255744)

19 August 2017

1 reference

title

Update on the management of lupus nephritis: let the treatment fit the patient (English)

1 reference

19 August 2017

1 reference

1 reference

George Bertsias

1

1 reference

PubMed ID

18756272

19 August 2017

Dimitrios T Boumpas

series ordinal

2

1 reference

19 August 2017

1 September 2008

1 reference

Nature Clinical Practice Rheumatology

19 August 2017

1 reference

19 August 2017

4

1 reference

19 August 2017

9

1 reference

19 August 2017

464-472

1 reference

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

19 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Treatment of membranous lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Mycophenolate therapy of SLE membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Lupus nephritis: treatment with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Premature atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0896

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0896

1 reference

19 August 2017

1 reference

PubMed ID

18756272